News Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors 10/27/22 Read more Expression & Characterization of Novel Tissue Selective E3 Ligases 10/25/22 Read more MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine 8/16/22 Read more Non-Clinical Safety Considerations when Developing Targeted Protein Degraders 5/10/22 Read more Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine 4/25/22 Read more Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics 4/25/22 Read more KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI) 4/7/22 Read more Undruggable Leaders Forum, September 15-16, 2021 9/15/21 Read more The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation 7/6/21 Read more Marking Kymera’s 5-Year Anniversary 6/7/21 Read more
